D-1836-2019 Class II Terminated

Recalled by Upsher Smith Laboratories, Inc. — Maple Grove, MN

FDA drug recall D-1836-2019 was initiated by Upsher Smith Laboratories, Inc. on Jul 29, 2019 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Aug 25, 2022). Affected quantity: 166 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 28, 2019
Initiation Date
Jul 29, 2019
Termination Date
Aug 25, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
166 bottles

Product description

Bexarotene Capsules, 75 mg, 100 capsules per bottle, Rx Only, Manufactured for: Upsher-Smith Laboratories, LLC, Maple Grove, MN 55369. NDC: 0832-0285-00

Reason for recall

Failed Dissolution Specifications

Distribution pattern

KY, OH, NJ, LA

Code information

Lot: A2610. exp 3/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1836-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1836-2019. Report a data issue: hello@regdatalab.com.